Spero Therapeutics (SPRO) EBITDA Margin (QoQ) (2016 - 2026)
Powered by 
Analysis
Spero Therapeutics (SPRO) EBITDA Margin (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 67.24 Mn | 16.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -299,775.00 |
| Dec 31, 2025 | 22,151.00 |
| Sep 30, 2025 | -12,824.00 |
| Jun 30, 2025 | 23,356.00 |
| Mar 31, 2025 | -10,637.00 |
| Dec 31, 2024 | -637.00 |
| Sep 30, 2024 | 4,888.00 |
| Jun 30, 2024 | -3,605.00 |
| Mar 31, 2024 | -21,961.00 |
| Dec 31, 2023 | 7,632.00 |
| Sep 30, 2023 | 46,700.00 |
| Jun 30, 2023 | 21,303.00 |
| Mar 31, 2023 | -74,227.00 |
| Dec 31, 2022 | 64,457.00 |
| Sep 30, 2022 | 71,865.00 |
| Jun 30, 2022 | 15,140.00 |
| Mar 31, 2022 | -45,772.00 |
| Dec 31, 2021 | -26,714.00 |
| Sep 30, 2021 | -37,494.00 |
| Jun 30, 2021 | -9,438.00 |